The best peptides for heart health, judged by evidence, are GLP-1-based drugs. Semaglutide 2.4 mg cut heart attacks, strokes and cardiovascular deaths by 20% in adults with heart disease and overweight or obesity (6.5% vs 8.0%), and Wegovy is FDA-approved for that use.[2][3] Tirzepatide reduced heart failure events in the SUMMIT trial.[9] Elamipretide (SS-31) is approved only for a rare genetic disease, and popular “heart repair” peptides such as TB-500 have no human heart data.[11][14]
“Best” here means best supported by trials, not most popular online. For the wider peptide landscape, see our longevity peptides hub.
Evidence at a glance
| Peptide or drug | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | FDA-approved for this use | 20% fewer major CV events in SELECT[2] | Approved to cut CV risk in adults with CVD and excess weight[3] | Semaglutide |
| Semaglutide and liraglutide (type 2 diabetes) | FDA-approved for this use | Fewer major CV events in SUSTAIN-6 and LEADER[5][4] | Approved CV indications in type 2 diabetes | Liraglutide |
| Tirzepatide | Human RCTs | Fewer HFpEF events (9.9% vs 15.3%) in SUMMIT[9] | Mounjaro has a CV indication in type 2 diabetes;[7] no heart failure indication | Tirzepatide |
| Semaglutide in HFpEF | Human RCTs | Better symptoms and walking distance in STEP-HFpEF[8] | No separate heart failure indication[3] | Semaglutide |
| Elamipretide (SS-31, Forzinity) | FDA-approved for a rare disease only | Knee strength in Barth syndrome[11] | Accelerated approval for Barth syndrome only | SS-31 |
| TB-500 (thymosin beta-4 fragment) | Animal or lab only | Heart cell repair in mice[13] | Not approved[14] | TB-500 |
| BPC-157 | No evidence, marketing only | No human heart trials | Not approved[14] | BPC-157 |
Standard heart care comes first
The foundations of heart health are not peptides. The American Heart Association’s Life’s Essential 8 lists the factors with the strongest link to heart health: healthy eating, physical activity, avoiding nicotine, good sleep, a healthy weight, and controlled cholesterol, blood sugar and blood pressure.[1] For people with heart disease, proven medicines such as statins and blood pressure drugs remain the base of treatment.
The GLP-1 heart trials below added the drug on top of standard care. None tested a peptide as a replacement for it.
Semaglutide: the SELECT trial
SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, none with diabetes. Participants had to be 45 or older with a body mass index (BMI) of 27 or higher, and they were randomly assigned to weekly semaglutide 2.4 mg or placebo. The trial was funded by the manufacturer. Over a mean of about 40 months:[2]
- Heart attack, stroke or cardiovascular death: 6.5% on semaglutide 2.4 mg versus 8.0% on placebo (hazard ratio 0.80).
- Stopping the drug due to side effects: 16.6% versus 8.2%, mostly from stomach problems.
FDA approved Wegovy to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.[3]
In type 2 diabetes, weekly semaglutide lowered major cardiovascular events to 6.6% from 8.9% in SUSTAIN-6,[5] and daily liraglutide lowered them to 13.0% from 14.9% in LEADER, with fewer cardiovascular deaths.[4] Our GLP-1 heart outcomes guide covers every major trial.
Heart failure with preserved ejection fraction (HFpEF)
HFpEF is heart failure in which the heart pumps normally but is stiff, and it is closely linked to obesity.
STEP-HFpEF (semaglutide). In 529 people with HFpEF and obesity, semaglutide 2.4 mg improved a heart failure symptom score by 16.6 points versus 8.7 on placebo, increased 6-minute walk distance by 20 meters more and produced 13.3% weight loss versus 2.6%. Serious adverse events were less common on semaglutide (13.3% vs 26.7%).[8]
SUMMIT (tirzepatide). In 731 people with HFpEF and obesity, cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide versus 15.3% on placebo over a median of two years. That gap came from fewer worsening heart failure events (8.0% vs 14.2%); cardiovascular deaths were few and similar (2.2% vs 1.4%).[9] Participants had an ejection fraction of at least 50% and a BMI of 30 or more, and received up to 15 mg weekly. Symptom scores at one year improved by 19.5 points on tirzepatide versus 12.7 on placebo. Side effects, mainly digestive, led 6.3% to stop tirzepatide versus 1.4% on placebo.[9]
Neither drug’s current US label lists HFpEF as its own indication.[3][10] Many people with HFpEF and obesity already qualify through the weight-management indication, but that decision belongs to a cardiologist.
Tirzepatide in type 2 diabetes
In SURPASS-CVOT, 13,165 people with type 2 diabetes and heart disease received tirzepatide or dulaglutide, a GLP-1 drug with proven heart benefit. Major events occurred in 12.2% versus 13.1%: tirzepatide was as good as dulaglutide but not proven better.[6] Mounjaro’s label now includes reducing major cardiovascular events in high-risk adults with type 2 diabetes.[7] A separate outcomes trial in people with obesity, SURMOUNT-MMO, is due to finish in 2027.[16]
Elamipretide (SS-31): a narrow approval
Elamipretide is a small peptide that targets cardiolipin, a fat in the inner membrane of mitochondria. FDA granted Forzinity accelerated approval on September 19, 2025, for Barth syndrome, a rare inherited disease that often begins with severe heart failure in infancy. The approval was based on improved knee-extensor muscle strength, not heart outcomes, and a confirmatory trial is required.[11]
In its 12-person crossover trial, elamipretide missed its primary goals in the blinded phase; improvements appeared later in an open-label extension, which is weaker evidence.[12] It is not approved for ordinary heart failure or “heart health.” See our mitochondrial peptides guide for more.
Unproven “heart peptides”
- TB-500 is a fragment of thymosin beta-4. In a 2004 mouse study, thymosin beta-4 helped heart muscle cells survive and migrate after injury.[13] No human trial has tested TB-500 for heart disease.
- BPC-157 is marketed for blood vessel and heart repair based on animal studies only.
FDA lists both among bulk substances nominated for compounding that raised safety concerns, citing limited safety data and impurity risks.[14] Nesiritide, a lab-made natriuretic peptide once used in hospitals for acute heart failure, is now listed as discontinued.[15] Our natriuretic peptides guide explains how these heart hormones are used as blood tests.
For immune and longevity claims that often travel with these products, see thymosin alpha-1 vs LL-37 and peptides vs exosomes.
What to watch for on a GLP-1 drug
The Wegovy label notes that resting heart rate rose by an average of 1 to 4 beats per minute in weight-loss trials and advises checking heart rate at regular intervals.[3] Tell your clinician about a racing heartbeat at rest, and mention any planned surgery or sedation, since the label also warns about inhaling stomach contents during anesthesia.[3]
Questions to ask your cardiologist
- Do I qualify for semaglutide’s heart indication?
- Would a GLP-1 drug help my heart failure symptoms?
- How would it fit with my current heart medicines?
- What side effects should make me call you?
